

29 **Abstract**

30 **Background.** Understanding antibody responses to SARS-CoV-2 vaccination is crucial for
31 refining COVID-19 immunization strategies. Generation of mucosal immune responses,
32 including mucosal IgA, could be of potential benefit to vaccine efficacy, yet limited evidence
33 exists regarding the production of mucosal antibodies following the administration of current
34 mRNA vaccines to young children.

35 **Methods.** We measured the levels of antibodies against SARS-CoV-2 from a cohort of children
36 under 5 years of age undergoing SARS-CoV-2 mRNA vaccination (serially collected, matched
37 serum and saliva samples, N=116) or on convenience samples of children under 5 years of age
38 presenting to a pediatric emergency department (nasal swabs, N=103). Further, we assessed
39 salivary and nasal samples for the ability to induce SARS-CoV-2 spike-mediated neutrophil
40 extracellular traps (NET) formation.

41 **Results.** Longitudinal analysis of post-vaccine responses in saliva revealed the induction of
42 SARS-CoV-2 specific IgG but not IgA. Similarly, SARS-CoV-2 specific IgA was only observed in
43 nasal samples obtained from previously infected children with or without vaccination, but not in
44 vaccinated children without a history of infection. In addition, oronasopharyngeal samples
45 obtained from children with prior infection were able to trigger enhanced spike-mediated NET
46 formation, and IgA played a key role in driving this process.

47 **Conclusions.** Despite the induction of specific IgG in the oronasal mucosa, current
48 intramuscular vaccines have limited ability to generate mucosal IgA in young children. These
49 results confirm the independence of mucosal IgA responses from systemic humoral responses
50 following mRNA vaccination and suggest potential future vaccination strategies for enhancing
51 mucosal protection in this young age group.

52 **Major Article**

53 **INTRODUCTION**

54 While there is clear evidence that current COVID-19 mRNA vaccines induce robust and
55 protective systemic immune responses, the ability of these vaccines to induce mucosal
56 responses is less understood. Mucosal immune responses may provide additive benefits
57 potentially important for limiting transmission and increasing effectiveness against severe
58 disease [1]. It has been demonstrated in animal models that targeted nasal immunization, but
59 not intramuscular immunization, with ChAd-SARS-CoV-2 induces robust mucosal anti-IgA
60 responses with near sterilizing immunity, suggesting a role for mucosal IgA responses in
61 preventing SARS-CoV-2 infection and transmission [2]. Moreover, nasal SARS-CoV-2 specific
62 antibody responses have been associated with lower viral loads and milder systemic symptoms
63 of COVID-19 [3]. Studies on adults revealed that prior infection induces significantly higher
64 mucosal IgA than mRNA vaccination [4–6], underscoring the limited impact of intramuscular
65 vaccination on the induction of mucosal SARS-CoV-2 specific IgA in adults [7]. Young children
66 have developing immune systems with significantly reduced capacity to generate circulating
67 anti-SARS-CoV-2 IgA following vaccination as compared to adults [8]. However, studies
68 examining mucosal IgA responses in children following SARS-CoV2 mRNA vaccinations are
69 limited.

70 Here, we longitudinally evaluated both serological and salivary antibody responses in a
71 cohort of children under 5 years of age with and without a prior history of SARS-CoV-2 infection
72 following primary mRNA vaccination. We also compared antibody levels in nasal samples
73 obtained from children with a history of COVID-19, those with a prior history of vaccination,
74 those with both infection and vaccination, or those with neither. Additionally, we explored the
75 ability of spike-specific mucosal antibodies to induce neutrophil activation. Our results reveal
76 that while mRNA vaccination can generate robust systemic and mucosal IgG production,
77 vaccination alone has a limited ability to induce oronasopharyngeal IgA, nor does it boost
78 mucosal IgA levels induced by prior SARS-CoV-2 infection. Further, our data also suggest that
79 IgA produced in response to prior SARS-CoV-2 infection is a key driver of anti-SARS-CoV-2
80 antibody-induced neutrophilic activation.

81 **METHODS**

82 **Study Design**

83 Longitudinal cohort. Children aged 5 years or younger undergoing a COVID-19 mRNA
84 vaccination series were enrolled in this study. Informed consent was obtained from parents/legal
85 guardians. The IRB of Massachusetts General Hospital gave ethical approval for this work.
86 SARS-CoV-2 infection history and demographic information were obtained from electronic
87 medical records. Samples from individuals who were infected during the vaccine series were
88 excluded from this analysis. All subjects received either Pfizer (BNT162b2) or Moderna (mRNA-
89 173) for primary vaccine doses. Samples were collected before vaccination (V0) and 2-4 weeks
90 following the first, the second, and (in those receiving the Pfizer vaccine) the third vaccine doses
91 (V1, V2, V3, respectively). Saliva was collected by holding a SalivaBio swab (Salimetrics) under
92 the tongue for 2 minutes or until fully saturated. The saturated swab was then placed in the
93 upper chamber of the Swab Storage Tube (Salimetrics) and centrifuged at 450g at 4°C for 15
94 minutes. Saliva was collected, aliquoted, and stored at -80°C until use. Blood was collected via
95 venipuncture into serum separation tubes (BD) or by a microneedle capillary blood collection
96 device. Serum was collected, aliquoted, and stored at -80°C until use.

97 Emergency department convenience cohort. Children under 5 years old presenting to the
98 Emergency Department at Boston Children's Hospital (BCH) were enrolled in this study. Written
99 informed consent was acquired from parents/legal guardians. The IRB of Boston Children's
100 Hospital gave ethical approval for this work. Participants with a current positive SARS-CoV-2
101 PCR test were excluded from this study, and their vaccination status, prior infection status as
102 well as demographic information were obtained from a parental questionnaire. Following
103 completion of clinically indicated viral testing employing a nasopharyngeal swab, discarded viral
104 transport medium (VTM) was retrieved and stored at -80°C until use.

105 **Simoa anti-SARS-CoV-2 antibody measurements**

106 Saliva samples were diluted 64-fold in StartingBlock™ T20 blocking buffer (Thermo Fisher
107 Scientific) containing protease inhibitors (Halt™ Protease Inhibitor Cocktail, Thermo Fisher
108 Scientific). Single molecule array (Simoa) assays were then used to measure anti-S1, anti-RBD,
109 anti-spike, and anti-nucleocapsid antibodies, as previously described [9]. Briefly, using an HD-X
110 Analyzer (Quanterix Corporation, Billerica MA), the diluted samples were incubated with dye-
111 encoded magnetic beads coated with recombinant proteins. The beads were washed and
112 resuspended in a solution of biotinylated anti-human-IgG antibody. The beads were then
113 washed again and resuspended in a solution of streptavidin-conjugated β -galactosidase. Lastly,
114 the beads were resuspended in a solution of resorufin β -D-galactopyranoside and loaded into a

115 microwell array for imaging. Average enzymes per bead (AEB) values were calculated by the
116 HD-X software and normalized between runs using a COVID-19 positive serum standard.

117 **Nasal antibody detection**

118 VTM samples were thawed and centrifuged at 3000g for 5 mins. SARS-CoV-2 anti-S1, -S2, -
119 RBD and -Nucleocapsid IgG and IgA levels were determined using MILLIPLEX® SARS-CoV-2
120 Antigen Panel 1 IgG assay (Millipore Sigma, Cat. No. HC19SERG1-85K) and MILLIPLEX®
121 SARS-CoV-2 Antigen Panel 1 IgA assay (Millipore Sigma, Cat. No. HC19SERA1-85K),
122 respectively. The protocol was followed as described by the manufacturer, except 50µL/well of
123 undiluted VTM samples were used as the starting material, and an additional fixation step with
124 4% PFA was included following the final wash. Samples were analyzed using the Luminex™
125 200™ system. All samples were measured in duplicate, and control beads were used for
126 normalization.

127 **NETosis assay**

128 The NETosis assay was performed as previously described [10]. Briefly, microfluidic devices
129 were primed with RPMI media with no FBS. Neutrophils were isolated from healthy donors
130 using the Easysep Direct Neutrophil Isolation Kit (STEMCELL Technologies). Isolated
131 neutrophils were stained with 32 µM Hoeschst 3342 dye and mixed with SYTOX green (final
132 concentration 2 µM). Stained neutrophils were stimulated with either pooled saliva samples or
133 individual samples of VTM in the presence or absence of spike-coated NeutrAvidin beads. The
134 cell suspensions were then loaded into a microfluidic device and imaged with brightfield, FITC,
135 and DAPI fields every 10 minutes for 6 hours. NETosis was then quantified using FIJI and the
136 TrackMate plugin.

137 **Statistical analysis**

138 Two-tailed Mann-Whitney U tests were conducted to identify significant differences between
139 groups in GraphPad Prism version 10.1. Statistical significance is defined as *p < 0.05, **p <
140 0.01, ***p < 0.001, and ****p < 0.0001.

141 **RESULTS**

142 **mRNA vaccination fails to induce spike-specific IgA in saliva.**

143 To quantify mucosal and serologic antibody responses generated by COVID-19 mRNA
144 vaccination, we evaluated saliva and blood samples collected from healthy children with and
145 without prior history of COVID-19 based on their medical records (demographics shown in Table
146 1). Matched serum and saliva samples were collected longitudinally prior to vaccination and 4
147 weeks following each vaccine dose (Figure 1A). Participants were divided into two groups:
148 “Vaccine-only” (no prior infection) and “Vaccine/Infection” (with prior SARS-CoV-2 infection).
149 Consistent with the prior history, serum anti-nucleocapsid IgG levels were significantly higher in
150 the Vaccine/Infection group than in the Vaccine-only group (Figure 1B). As expected, prior to
151 vaccination (baseline, V0), we found significantly higher levels of anti-spike IgG and IgA in the
152 serum of participants in the Vaccine/Infection group than in the Vaccine-only group (Figure 1C).
153 Anti-spike IgG and IgA were significantly higher in serum collected following the completion of
154 vaccination (V2 or V3) than prior to vaccination in both groups, although levels of both IgG and
155 IgA remained higher in the Vaccine/Infection group than in the Vaccine-only group throughout
156 the time course (Figure 1C). Similar patterns were observed for both anti-S1 and anti-RBD
157 responses in serum samples (Figure S1).

158 Similar to responses in the serum, prior to vaccination, salivary anti-spike IgG was
159 significantly higher in the Vaccine/Infection group than in the Vaccination-only group, and was
160 significantly higher following completion of vaccination than prior to vaccination in both groups
161 (Figure 1D, left). Likewise, salivary levels of anti-spike IgG remained significantly higher in the
162 Vaccine/Infection group than in the Vaccine-only group throughout the time course, and similar
163 patterns were observed for salivary anti-S1 and anti-RBD IgG (Figure S2A). While levels of anti-
164 spike IgA in the saliva at baseline were also significantly higher in the Vaccine/Infection group
165 than in the Vaccine-only group, we were unable to detect a significant increase in levels of anti-
166 spike IgA in either group following vaccination (Figure 1D, right). Small but statistically
167 significant increases in the levels of anti-S1 IgA but not in anti-RBD IgA were observed in the
168 Vaccine-only group following vaccination (Figure S2B). Taken together, these observations
169 suggest that the ability of COVID-19 mRNA vaccination to induce salivary IgA is quite limited.

170

171 **mRNA vaccination fails to induce anti-spike IgA in the nasal mucosa**

172 To further evaluate nasopharyngeal antibody levels following mRNA vaccination and/or
173 SARS-CoV-2 infection, we collected viral transport media (VTM) samples used for testing of
174 material collected on nasopharyngeal swabs obtained from a convenience cohort of children

175 under 5 years of age presenting to a pediatric emergency department for evaluation of
176 respiratory symptoms (demographics shown in Table 2). Children who tested positive for acute
177 SARS-CoV-2 infection were excluded from this study. Children were categorized into 4 groups
178 based on parental recall of COVID-19 mRNA vaccination and evidence of prior SARS-CoV-2
179 infection (presence of anti-nucleocapsid IgG in the VTM): No history of vaccination or evidence
180 of SARS-CoV-2 infection (“Negative”), history of vaccination only (“Vaccine-only”), evidence for
181 SARS-CoV-2 infection only (“Prior Infection”), and a history of both (“Vaccine/Infection”). We
182 found that SARS-CoV-2-specific IgG levels were significantly higher in the Vaccine-only,
183 Vaccine/Infection, and Prior Infection groups compared to the Negative group (Figure 2B),
184 suggesting effective induction of SARS-CoV-2 specific IgG within the nasal mucosa by either
185 vaccination or natural infection. Notably, levels of nasal IgG were significantly higher in children
186 who were both vaccinated and had a prior SARS-CoV-2 infection compared to all other groups,
187 indicating that COVID-19 mRNA vaccination likely boosts nasal IgG levels in participants
188 previously infected with SARS-CoV-2.

189 In contrast, nasal anti-S1, anti-S2, and anti-RBD IgA levels were significantly higher in the
190 Vaccine/Infection and Prior Infection groups than in both the Negative and Vaccine-only groups,
191 and we were unable to detect a significant difference in anti-S1 or anti-RBD IgA levels between
192 the Vaccine-only group and the Negative group, nor between the Vaccine/Infection group and
193 the Prior infection group (Figure 2C). We did detect a small but significant increase in anti-S2
194 IgA levels between the Vaccine-only group and the Negative group, although we did not
195 appreciate a significant increase in anti-S2 IgA between the Vaccine/Infection group and the
196 Prior Infection group. Similar to results with saliva, these results indicate that despite the ability
197 to induce mucosal IgG, the ability of COVID-19 mRNA vaccination to induce SARS-CoV-2
198 specific IgA in the nasal mucosa is quite limited.

199

200 **SARS-CoV-2 specific salivary and nasal antibodies trigger extensive spike-mediated** 201 **neutrophil activation**

202 Neutrophils are abundant in the nasal mucosa of healthy children, and exhibit a more
203 activated phenotype than neutrophils in the adult nose following SARS-CoV-2 infection [11].
204 However, whether SARS-CoV-2 specific antibodies in the oronasopharynx have the ability to
205 activate neutrophils following antigen exposure is not fully defined, and further, the role of
206 mucosal IgA in this process remains to be determined. To examine whether mucosal antibodies
207 induced by vaccination and/or natural infection have the ability to activate neutrophils and
208 induce the formation of neutrophil extracellular traps (NET), we pooled saliva samples from

209 healthy children with completed vaccine doses in the following groups: “Negative” (no prior
210 infection or vaccination), “Vaccine-only” (vaccinated individuals without history of COVID-19)
211 and “Vaccine/Infection” (vaccinated individuals with prior infection) (N=4 samples per pool) to
212 obtain sufficient volumes of saliva to evaluate NET formation. We then mixed these pooled
213 saliva samples with spike protein-coated beads to induce immune complex formation and added
214 these mixtures to neutrophils isolated from four healthy individuals. We assessed neutrophil
215 activation by quantification of the percentage of neutrophils that undergo NETosis (Figure 3A).
216 None of the sample pools induced NETosis in the absence of spike protein, but we observed
217 significant increases in NETosis following the addition of spike protein to the Vaccine-only pool
218 and the Vaccine/Infection pool, but not from the Negative pool (Figure 3B), consistent with the
219 presence of antibodies with the ability to induce anti-spike immune complexes in these pools.
220 Interestingly, the level of NETosis was higher in the Vaccine/Infection pool than in the Vaccine-
221 only pool, likely reflecting the higher levels of salivary anti-SARS-CoV-2 antibodies, although the
222 analysis of a single pool limits our ability to evaluate significance across pools assembled from
223 the different groups. To address this potential limitation, we compared the ability of a subset of
224 nasal samples (N=4 per group) to induce NETosis following exposure to spike protein-coated
225 beads (Figure 3C). Antibody levels for each individual sample used in this assay are shown in
226 Figure S3. The induction of NETosis was significantly higher in Vaccine-only, Vaccine/Infection,
227 and Prior Infection groups than in the Negative group, and we observed significantly higher
228 levels of NETosis in the Vaccine/Infection group than in all other groups (Figure 3D). Taken
229 together, these results confirm that higher levels of antibodies observed within the oronasal
230 mucosa of vaccinated children with a prior SARS-CoV-2 infection are associated with an
231 enhanced neutrophil activation, likely signifying functional importance.

232

233 **Spike-specific IgA in saliva acts as a key inducer of neutrophil activation**

234 To better understand which subclass of antibodies drives the NETosis observed in salivary
235 samples, we depleted either IgG, IgA, or both from pooled saliva samples and evaluated
236 neutrophil activation following the addition of spike protein-coated beads (Figure 4A). We found
237 that depletion of either IgG or IgA from the Vaccine-only or Vaccine/Infection pools significantly
238 inhibited NETosis and that NETosis was eliminated by depletion of both IgG and IgA (Figure 4B
239 and 4C). Thus, both IgG and IgA contribute to the ability of oronasal mucosal antibodies to
240 induce SARS-CoV-2 specific neutrophil activation in children exposed and/or immunized to the
241 virus. One inconsistency we noted is that IgA depletion in Vaccine-only saliva pool significantly
242 inhibited the neutrophil NET formation, even though we did not observe significant induction of

243 mucosal IgA by vaccination alone. We believe that a non-specific ability of IgA in saliva to
244 induce NET formation is unlikely, given that saliva from children without a history of COVID-19
245 did not induce NET formation prior to vaccination. Rather, we suspect that vaccination alone
246 does result in low levels of mucosal IgA potentially from passive transport from serum and that
247 we were unable to detect significant differences in levels of nasal IgA between the unvaccinated
248 and vaccinated groups given our sample size limitations. Future studies with larger sample
249 sizes will be necessary to definitively answer this question.

250 **DISCUSSION**

251 In June 2022, the FDA granted approval for the administration of the COVID-19 mRNA
252 vaccine to children aged 6 months to 5 years, however over 95% of children have been
253 exposed to SARS-CoV-2 based on national serological surveillance testing [12]. Thus, it is
254 essential to conduct a thorough evaluation of both systemic and mucosal humoral responses
255 triggered by immunization in children under 5 years of age with and without prior infection.

256 The robust anti-spike IgG and IgA responses we observed in serum post-vaccination aligned
257 with the broader consensus regarding the efficacy of current mRNA vaccine in inducing
258 systemic immunity. In addition, we revealed that vaccination induced mucosal IgG responses in
259 children, though hybrid immunity induced the highest level of SARS-CoV-2 specific IgG. Our
260 observation of close correlation between systemic and mucosal IgG levels is consistent with
261 models in which IgG accumulates in the mucosa as the result of passive transport from the
262 circulatory system [13]. In contrast, our study highlighted the limited ability of these vaccines to
263 generate mucosal IgA responses, and confirms that mucosal IgA production in the
264 oronasopharynx can be largely independent of systemic IgA responses [14]. IgA is recognized
265 as an important factor in mucosal immunity regarding its role in neutralizing pathogens,
266 particularly in the gastrointestinal tract and the upper airways [15]. Notably, mucosal IgA has
267 been identified as a critical antibody type protecting against SARS-CoV-2 infection [16,17] and
268 correlates with reduced viral infectivity *in vitro* [18]. Our findings raised questions about the
269 completeness of protection conferred by the current immunization strategies, although the exact
270 function of viral-specific mucosal IgA still requires further investigation.

271 Another crucial aspect of our study involves the exploration of mucosal antibody-induced
272 neutrophil activation, as demonstrated by the assessment of neutrophil extracellular traps
273 induced by salivary and nasal samples from infected and/or immunized individuals. Neutrophils
274 have been shown to release NETs as an antimicrobial defense at the mucosa, helping to clear
275 pathogens to prevent more severe infection and disease [19,20]. Also, children have abundant
276 neutrophils in their airways, which may contribute to the rapid viral clearance and mild disease
277 observed in children [11,21,22]. In our study, we found that vaccine and infection-induced
278 mucosal antibodies were likely generating immune complexes upon spike protein challenge,
279 resulting in enhanced NET formation. Furthermore, we identified the critical role of mucosal IgA
280 in driving spike-mediated NETosis, suggesting the generation of SARS-CoV-2 specific mucosal
281 IgA is a key component for providing enhanced protection against subsequent infections. While
282 mucosal IgA immune complexes are the most potent inducer of NETs, IgG immune complexes
283 were also able to induce NETs, albeit to a lesser degree, supporting that vaccination, through

284 induction of mucosal IgG, provides some degree of mucosal protection which may contribute to
285 more rapid clearance of virus in vaccinated as compared to unvaccinated individuals [23].

286 Vaccination in previously infected individuals provided the most abundant SARS-CoV-2 specific
287 IgG, emphasizing the potential importance of continued vaccination efforts in this population.

288 Our study was limited by a relatively small sample size, however, we overcame numerous
289 challenges in obtaining blood and mucosal samples from young pediatric cohorts with low rates
290 of vaccination. Thus, this sized cohort is substantial enough to offer meaningful insights. Further,
291 we utilized non-invasive samples such as saliva and nasopharyngeal swabs to demonstrate
292 how mucosal immunity compared with systemic immunity.

293 In conclusion, our study confirms the ability of COVID-19 mRNA vaccines to induce mucosal
294 in addition to systemic IgG in previously uninfected young children. However, the limited
295 generation of mucosal IgA responses following vaccination underscores a potential area for
296 improvement in current vaccination strategies for this specific demographic. Further research is
297 warranted to explore alternative vaccine formulations or strategies that may enhance mucosal
298 immunity in young children, contributing to more comprehensive protection against SARS-CoV-
299 2.

300 **FUNDING**

301 We acknowledge funding from NIH (NHLBI 5K08HL143183 to L.M.Y.), Massachusetts General
302 Hospital Department of Pediatrics (L.M.Y.), Boston Children's Hospital Department of Pediatrics
303 (B.H.H.), and the Chan-Zuckerberg Initiative (B.H.H.).

304

305 **ACKNOWLEDGEMENT**

306 Study design/funding: B.H.H., L.M.Y.; Data acquisition and analysis: Y.T., B.P.B., Z.N.S., E.B.,
307 S.C.; Patient consent and sample collection: W.I.G., M.D., M.A.F.L., A.F., M.D., R.L.W., J.G.,
308 J.S., Y.T.; Manuscript writing: Y.T.; Figure generation: Y.T., B.P.B.; Supervision: D.R.W., B.H.H.,
309 L.M.Y.; All authors reviewed and approved the final version of the manuscript.

310


311 We express extreme gratitude to all of the young children and families who participated in our
312 study.

313

314 **CONFLICT OF INTEREST**

315 David Walt has a financial interest in Quanterix Corporation, a company that develops an ultra-
316 sensitive digital immunoassay platform. He is an inventor of the Simoa technology, a founder of
317 the company, and also serves on its Board of Directors. Dr. Walt's interests were reviewed and
318 are managed by Brigham and Women's Hospital and Partners Healthcare in accordance with
319 their conflict of interest policies.

320 **FIGURES**



321 **Figure 1. SARS-CoV-2 mRNA vaccination fails to induce spike-specific IgA in saliva.**

322 **(A)** Schematic overview of study design and sample collection timeline. **(B)** Serum anti-

323 nucleocapsid IgG level indicates prior SARS-CoV-2 infection status. Anti-nucleocapsid IgG are

324 shown for groups with and without a prior history of COVID-19. **(C)** Serum anti-spike IgG (left)

325 and IgA (right) levels are shown. Differences between groups are shown as black asterisks.


326 Differences between time points within groups are shown as blue or orange asterisks. Error bar

327 represents the mean value and the standard deviation. Two-tailed Mann-Whitney U tests were

328 performed between individual groups, and statistical significance is defined as * $p < 0.05$, ** $p <$

329 0.01 , *** $p < 0.001$, and **** $p < 0.0001$.

331




332


333 **Figure 2. SARS-CoV-2 mRNA vaccination fails to induce anti-spike IgA in the nasal**
334 **mucosa.**

335 **(A)** Schematic overview of study design and experimental procedures. **(B-C)** Nasal anti-S1, -S2,
336 -RBD, and -Nucleocapsid IgG (B) and IgA (C) levels were plotted, and comparisons among four
337 groups were conducted. Error bar represents the mean value and the standard deviation. Two-
338 tailed Mann-Whitney U tests were performed, and statistical significance is defined as * $p < 0.05$,
339 ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$.

340




341
342 **Figure 3. SARS-CoV-2 specific salivary and nasal antibodies trigger extensive spike-**
343 **mediated neutrophil activation.**
344 **(A)** Schematic overview of spike-mediated NETosis assay using saliva pools. **(B)** Comparison of
345 %NETosis in the presence (white bars) or absence (gray bars) of spike-coated beads in the
346 Negative, Vaccine-only, and Vaccine/Infection pools. **(C)** Schematic overview of spike-specific
347 NETosis assay using individual nasal samples (N=4 per group). **(D)** Percent NETosis of
348 neutrophils stimulated by spike-coated beads with nasal samples from Negative, Vaccine-only,
349 Vaccine/Infection, and Prior Infection groups. Error bar represents the mean value and the
350 standard deviation. Two-tailed Mann-Whitney U tests were performed, and statistical
351 significance is defined as *p < 0.05.
352



353
 354 **Figure 4. Depletion of mucosal antibodies interferes with the neutrophil activation**
 355 **induced by saliva pools from individuals in the Vaccine-only and Vaccine/Infection group.**
 356 **(A)** Schematic overview of antibody depletion assay in salivary samples. **(B-C)** End-point
 357 percentage of NETs released from neutrophils stimulated with saliva from the Vaccine-only pool
 358 (B) and the Vaccine/Infection pool (C) following depletion of IgG, IgA, or both IgG and IgA. Black
 359 dots represent NETs released from neutrophils stimulated with the Negative saliva pool in the
 360 presence of spike-coated beads. Error bar represents the mean value and the standard
 361 deviation. Two-tailed Mann-Whitney U tests were performed, and statistical significance is
 362 defined as * $p < 0.05$.

363




364
365

Figure S1. Vaccination induces anti-S1/-RBD IgG and IgA in the serum.

366 **(A)** Serum anti-S1 (left) and anti-RBD (right) IgG levels are shown. **(B)** Serum anti-S1 (left) and
367 anti-RBD (right) IgA levels are shown. Differences between groups are shown as black
368 asterisks. Differences between time points within groups are shown as blue or orange asterisks.
369 Error bar represents the mean value and the standard deviation. Two-tailed Mann-Whitney U
370 tests were performed, and statistical significance is defined as * $p < 0.05$, ** $p < 0.01$, *** $p <$
371 0.001 , and **** $p < 0.0001$.

372
373



374

375

Figure S2. Vaccination induces salivary anti-S1/-RBD IgG but not IgA.

376

(A) Saliva anti-S1 (left) and anti-RBD (right) IgG levels are shown. **(B)** Saliva anti-S1 (left) and

377

anti-RBD (right) IgA levels are shown. Differences between groups are shown as black

378


asterisks. Differences between time points within groups are shown as blue or orange asterisks.

379

Error bar represents the mean value and the standard deviation. Two-tailed Mann-Whitney U

380

tests were performed, and statistical significance is defined as *p < 0.05 and **p < 0.01.



381

382 **Figure S3. Levels of SARS-CoV-2 specific IgG and IgA in nasal samples evaluated in**

383 **Figure 3D.**

384 Levels of Anti-S1, Anti-S2, Anti-RBD, and Anti-Nucleocapsid IgG **(A)** and IgA **(B)** in the 4

385 selected nasal samples from each group used for NETosis assay. Two-tailed Mann-Whitney U

386 tests were performed, and statistical significance is defined as * $p < 0.05$.

387

388 **TABLES**

| | Saliva | | | | Serum | | | |
|--------------------------------|----------------|----------------|----------------|---------------|----------------|----------------|----------------|---------------|
| | V0 (N = 14) | V1 (N = 17) | V2 (N = 13) | V3 (N = 4) | V0 (N = 19) | V1 (N = 23) | V2 (N = 20) | V3 (N = 6) |
| Age (month) | | | | | | | | |
| Minimum | 6.87 | 6.87 | 6.87 | 6.81 | 9.24 | 6.87 | 6.87 | 6.97 |
| Median (IQR) | 12.72 (2.2) | 13.74 (15.4) | 13.05 (29) | 12.86 (10.7) | 13.74 (29.8) | 13.74 (15.6) | 14.28 (29.4) | 12.85 (26) |
| Maximum | 55.53 | 55.53 | 55.53 | 48.46 | 55.53 | 55.53 | 55.53 | 48.46 |
| Sex | | | | | | | | |
| Female | 7 (50%) | 8 (47.1%) | 6 (46.2%) | 2 (50%) | 8 (42.1%) | 11 (47.8%) | 10 (50%) | 4 (66.7%) |
| Male | 7 (50%) | 9 (52.9%) | 7 (53.8%) | 2 (50%) | 11 (57.9%) | 12 (52.2%) | 10 (50%) | 2 (33.3%) |
| Race | | | | | | | | |
| White | 11 (78.6) | 9 (52.9%) | 8 (61.5%) | 4 (100%) | 12 (63.1%) | 12 (52.2%) | 12 (60%) | 5 (83.3%) |
| Black/African American | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4.3%) | 0 (0%) | 0 (0%) |
| Asian | 0 (0%) | 2 (11.8%) | 1 (7.7%) | 0 (0%) | 3 (15.8%) | 3 (13%) | 3 (15%) | 0 (0%) |
| Other/Unknown | 3 (21.4) | 6 (35.3) | 4 (30.8%) | 0 (0%) | 4 (21.1%) | 7 (30.4%) | 5 (25%) | 1 (16.7%) |
| Ethnicity | | | | | | | | |
| Hispanic | 0 (0%) | 0 (0%) | 0 (0%) | 4 (100%) | 0 (0%) | 1 (4.3%) | 0 (0%) | 0 (0%) |
| Not Hispanic | 9 (64.3%) | 9 (52.9%) | 8 (61.5%) | 0 (0%) | 13 (68.4%) | 13 (56.5%) | 13 (65%) | 5 (83.3%) |
| Unknown | 5 (35.7%) | 8 (47.1%) | 5 (38.5%) | 0 (0%) | 6 (31.6%) | 9 (39.1%) | 7 (35%) | 1 (16.7%) |
| COVID-19 Vaccine Status | | | | | | | | |
| Not vaccinated | 14 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 19 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Pfizer-BioNTech | 0 (0%) | 5 (29.4) | 5 (38.5%) | 4 (100%) | 0 (0%) | 15 (65.2%) | 7 (35%) | 6 (100%) |
| Moderna | 0 (0%) | 12 (70.6%) | 8 (61.5%) | 0 (0%) | 0 (0%) | 8 (34.8%) | 13 (65%) | 0 (0%) |

389

390 **Table 1. Characteristics of participants in longitudinal cohort.**

391

| | Negative (N = 23) | Vaccine-only (N = 22) | Vaccine/Infection (N = 22) | Prior Infection (N = 36) |
|--------------------------------|-----------------------------|---------------------------------|--------------------------------------|------------------------------------|
| Age (month) | | | | |
| Minimum | 5 | 8 | 3 | 2 |
| Median (IQR) | 24 (24) | 18.5 (24) | 29 (25) | 25.5 (22) |
| Maximum | 47 | 57 | 53 | 58 |
| Sex | | | | |
| Female | 5 (21.7%) | 9 (40.9%) | 12 (54.5%) | 17 (47.2%) |
| Male | 18 (78.3%) | 13 (59.1%) | 10 (45.5%) | 19 (52.8%) |
| Race | | | | |
| White | 6 (26.1%) | 11 (50%) | 7 (31.8%) | 12 (33.3%) |
| Black/African American | 3 (13%) | 1 (4.5%) | 3 (13.6%) | 4 (11.1%) |
| Asian | 2 (8.7%) | 3 (13.6%) | 0 (0%) | 3 (8.3%) |
| Other/Unknown | 12 (52.2%) | 7 (31.8%) | 12 (54.5%) | 17 (47.2%) |
| Ethnicity | | | | |
| Hispanic | 5 (21.7%) | 0 (0%) | 6 (27.3%) | 10 (27.8%) |
| Not Hispanic | 12 (52.2%) | 13 (59.1%) | 8 (36.4%) | 16 (44.4%) |
| Unknown | 6 (26.1%) | 9 (40.9%) | 8 (36.4%) | 10 (27.8%) |
| COVID-19 Vaccine Status | | | | |
| Not vaccinated | 23 (100%) | 0 (0%) | 0 (0%) | 36 (100%) |
| Pfizer-BioNTech | 0 (0%) | 9 (40.9%) | 9 (40.9%) | 0 (0%) |
| Moderna | 0 (0%) | 9 (40.9%) | 8 (36.4%) | 0 (0%) |
| Not known | 0 (0%) | 4 (18.2%) | 5 (22.7%) | 0 (0%) |

392

393

394

Table 2. Characteristics of participants in emergency department convenience cohort.

395 **References**

396

- 397 1. Mettelman RC, Allen EK, Thomas PG. Mucosal immune responses to infection and
398 vaccination in the respiratory tract. *Immunity* **2022**; 55:749–780.
- 399 2. Hassan AO, Kafai NM, Dmitriev IP, et al. A Single-Dose Intranasal ChAd Vaccine Protects
400 Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell* **2020**; 183:169-184.e13.
- 401 3. Fröberg J, Gillard J, Philipsen R, et al. SARS-CoV-2 mucosal antibody development and
402 persistence and their relation to viral load and COVID-19 symptoms. *Nat Commun* **2021**;
403 12:5621.
- 404 4. Sano K, Bhavsar D, Singh G, et al. SARS-CoV-2 vaccination induces mucosal antibody
405 responses in previously infected individuals. *Nat Commun* **2022**; 13:5135.
- 406 5. Bhavsar D, Singh G, Sano K, et al. Mucosal antibody responses to SARS-CoV-2 booster
407 vaccination and breakthrough infection. *mBio* **2023**; 14:e02280-23.
- 408 6. Nantel S, Sheikh-Mohamed S, Chao GYC, et al. Comparison of Omicron Breakthrough
409 Infection Versus Monovalent SARS-CoV-2 Intramuscular Booster Reveals Differences in
410 Mucosal and Systemic Humoral Immunity. *Mucosal Immunol* **2024**;
- 411 7. Roubidoux EK, Bringleb PH, Vegesana K, et al. Utility of nasal swabs for assessing mucosal
412 immune responses towards SARS-CoV-2. *Sci Rep* **2023**; 13:17820.
- 413 8. Nziza N, Deng Y, Wood L, et al. Humoral profiles of toddlers and young children following
414 SARS-CoV-2 mRNA vaccination. *Nat Commun* **2024**; 15:905.
- 415 9. Norman M, Gilboa T, Ogata AF, et al. Ultrasensitive high-resolution profiling of early
416 seroconversion in patients with COVID-19. *Nat Biomed Eng* **2020**; 4:1180–1187.
- 417 10. Boribong BP, LaSalle TJ, Bartsch YC, et al. Neutrophil profiles of pediatric COVID-19 and
418 multisystem inflammatory syndrome in children. *Cell Rep Med* **2022**; 3:100848.
- 419 11. Loske J, Röhmel J, Lukassen S, et al. Pre-activated antiviral innate immunity in the upper
420 airways controls early SARS-CoV-2 infection in children. *Nat Biotechnol* **2022**; 40:319–324.
- 421 12. CDC COVID Data Tracker: Pediatric Seroprevalence. Available at:
422 <https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence>. Accessed 14 March 2024.
- 423 13. Spiekermann GM, Finn PW, Ward ES, et al. Receptor-mediated Immunoglobulin G
424 Transport Across Mucosal Barriers in Adult Life. *J Exp Med* **2002**; 196:303–310.
- 425 14. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. Mucosal Immunity in COVID-19: A
426 Neglected but Critical Aspect of SARS-CoV-2 Infection. *Front Immunol* **2020**; 11:611337.

- 427 15. Bemark M, Angeletti D. Know your enemy or find your friend?—Induction of IgA at
428 mucosal surfaces. *Immunol Rev* **2021**; 303:83–102.
- 429 16. Havervall S, Marking U, Svensson J, et al. Anti-Spike Mucosal IgA Protection against
430 SARS-CoV-2 Omicron Infection. *New Engl J Med* **2022**;
- 431 17. Verheul MK, Kaczorowska J, Hofstee MI, et al. Protective mucosal SARS-CoV-2 antibodies
432 in the majority of the general population in the Netherlands. *Mucosal Immunol* **2024**;
- 433 18. Ellis S, Way R, Nel M, et al. Salivary IgA and vimentin differentiate in vitro SARS-CoV-2
434 infection: a study of 290 convalescent COVID-19 patients. *Mucosal Immunol* **2023**;
- 435 19. Mohanty T, Sjögren J, Kahn F, et al. A novel mechanism for NETosis provides antimicrobial
436 defense at the oral mucosa. *Blood* **2015**; 126:2128–2137.
- 437 20. Hwang JW, Kim JH, Kim HJ, et al. Neutrophil extracellular traps in nasal secretions of
438 patients with stable and exacerbated chronic rhinosinusitis and their contribution to induce
439 chemokine secretion and strengthen the epithelial barrier. *Clin Exp Allergy* **2019**; 49:1306–1320.
- 440 21. Yonker LM, Boucau J, Regan J, et al. Virologic features of SARS-CoV-2 infection in
441 children. *J Infect Dis* **2021**; 224:jjab509-.
- 442 22. Yonker LM, Neilan AM, Bartsch Y, et al. Pediatric Severe Acute Respiratory Syndrome
443 Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses. *J*
444 *Pediatr* **2020**; 227:45-52.e5.
- 445 23. Pilapitiya D, Wheatley AK, Tan H-X. Mucosal vaccines for SARS-CoV-2: triumph of hope
446 over experience. *eBioMedicine* **2023**; 92:104585.
- 447